Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of targeted therapies as a possible treatment
for estrogen-receptor positive (ER+) endometrial cancer.
The drugs involved in this study are:
- Abemaciclib (also known as Verzenio™)
- Letrozole (also known as Femara®)